Skip to content

Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention

Pilot Trial of a Real-time Electronic Adherence Monitoring Intervention for Antiretroviral Therapy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06550804
Acronym
A-TEAM
Enrollment
126
Registered
2024-08-13
Start date
2024-10-01
Completion date
2027-03-01
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence, Medication, HIV Infections

Brief summary

The investigators propose using an electronic adherence device that is basically a pill container that can alert when it is not opened at a scheduled time. The investigators will use this device to alert the medication user at the time when medication is supposed to be taken if the device did not get opened and a pre-identified social support person or case manager when 2 or 7 consecutive days of nonadherence are detected, respectively. The investigators call our approach "A-Team" (Antiretroviral Therapy Electronic Adherence Monitoring). The aims of this application are to determine the acceptability and feasibility of real-time adherence monitoring in support persons and case managers of African American Men who have sex with Men and to test this approach for these men in a 6-month randomized controlled trial among 54 of these men living with HIV and measure ART adherence and viral suppression (the primary outcome).

Detailed description

African American men who have sex with men (AAMSM) have high HIV infection rates and disproportionate mortality. Critical to ending the HIV epidemic are efforts to reduce HIV transmission by optimizing antiretroviral adherence and suppressing viral load. The investigators propose using responsive electronic adherence monitoring (EAM) in a tiered approach from least to most resource utilization where the EAM device alerts the medication user at the time non-adherence is detected and a pre-identified social support person or case manager when 2 or 7 consecutive days of nonadherence are detected, respectively. The investigators call our approach "A-Team" (Antiretroviral Therapy Electronic Adherence Monitoring) because we provide a team serving a common goal to persons struggling with adherence. This intervention draws on the situated Information Motivation Behavioral Skills Model and is informed by emerging social support literature. Real-time ART adherence monitoring with a triaged response to missed doses informs the patient in real-time of each potential non-adherence event, motivates medication adherence, and positively influences adherence behavioral skills, resulting in viral suppression. This study will be the first to discover how social support persons and case managers perceive this approach, what concerns they may have, and how they respond to one or multiple notifications of missed doses. The aims of this application are to determine the acceptability and feasibility of real-time adherence monitoring in support persons and case managers of AAMSM and to pilot a triaged responsive real-time monitoring adherence intervention for AAMSM. The investigators will implement a 6-month pilot randomized controlled trial among 54 AAMSM living with HIV and measure ART adherence and viral suppression (the primary outcome). Lessons learned from this project may be useful to the field of adherence in these and other persons living with HIV and other diseases.

Interventions

BEHAVIORALA-TEAM

Participants randomized to the intervention arm will receive the proposed intervention, which involves an electronic adherence device called Wisepill and triaged text alerts to the user, the social support, and the case manager for same day, two day, and seven day device non-openings.

Sponsors

University of Illinois at Chicago
Lead SponsorOTHER
Massachusetts General Hospital
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

One group receives intervention and one groups receives routine care only.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Participant inclusion criteria: * AAMSM \>18 years with self-reported HIV infection; * own a working cell phone; * on ART for at least 6 months; * have a case manager willing to participate in the study (for the clinical trial); and * have suboptimal adherence - either have a detectable viral load in the past 6 months, self-reported \<90% adherence based on a 3-item measure or referral by their healthcare provider because of a recognized problem with ART adherence. For social support persons, participants will: * report that they have a self-described meaningful relationship with the participant; * be \>18 years of age; * own a working cell phone and; * be willing to provide support. For case managers, participants will have worked with clients with HIV at least 6 months prior to their participation in this study and own a working cell phone.

Exclusion criteria

* Not meeting the inclusion criteria * Not agreeing to informed consent concerning interactions with research team, data collection, and access to medical records. * Candidates must provide consent to obtain a copy of their viral load results during the 12 months before and following study onset to confirm eligibility and explore long-term follow-up of possible effect.

Design outcomes

Primary

MeasureTime frameDescription
Viral load suppressionAt 6 months after introduction of the intervention.We measure HIV viral load

Secondary

MeasureTime frameDescription
AdherenceAt the end of month 1, month 2, month 3, month 4, month 5 and at 6 monthsReal-time and self-reported adherence

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMark Dworkin, MD

University of Illinois at Chicago

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026